HPR18 What Is the Impact of Including Outcomes-Based Agreements on the Cost-Effectiveness of Cell and Gene Therapies? A Case Example of Zynteglo for Transfusion-Dependent Beta Thalassemia
Abstract
Authors
M Richardson F Beaudoin D.M. Rind P Synnott B Herce-Hagiwara D Ollendorf